X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://endpts.com/secura-bio-to-keep-offering-blood-cancer-drug-despite-negative-odac-vote-os-questions/
https://www.prnewswire.com/news-releases/secura-bio-inc-receives-orphan-drug-designation-in-europe-for-duvelisib-for-the-treatment-of-patients-with-peripheral-t-cell-lymphoma-301713925.html
https://www.fiercepharma.com/pharma/fda-threatens-clamp-down-another-pi3k-blood-cancer-drug-time-full-approval
https://endpts.com/pi3k-inhibitor-hit-with-an-increased-death-risk-warning-from-fda-after-final-trial-results-emerge/
https://www.medpagetoday.com/hematologyoncology/leukemia/99556
https://www.prnewswire.com/news-releases/secura-bio-announces-the-presentation-of-new-copiktra-duvelisib-data-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas-ptcl-301444094.html
https://www.prnewswire.com/news-releases/secura-bio-announces-copiktra-duvelisib-strategic-focus-on-t-cell-lymphoma-and-voluntary-us-withdrawal-of-the-relapsed-or-refractory-follicular-lymphoma-indication-301436834.html
https://www.prnewswire.com/news-releases/copiktra-duvelisib-receives-european-union-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-cll-and-refractory-fl-301308685.html
https://www.prnewswire.com/news-releases/secura-bio-announces-enrollment-completion-of-the-copiktra-duvelisib-study-primo-in-peripheral-t-cell-lymphoma-301264723.html
https://www.prnewswire.com/news-releases/copiktra-duvelisib-receives-positive-chmp-opinion-for-the-treatment-of-relapsed-and-refractory-cll-and-refractory-fl-301260777.html
http://www.pharmatimes.com/news/five_new_meds_recommended_in_march_chmp_decisions_1365972
https://www.prnewswire.com/news-releases/secura-bio-completes-acquisition-of-global-rights-to-oncology-drug-copiktra-301141959.html
https://www.biospace.com/article/releases/verastem-oncology-announces-closing-of-copiktra-duvelisib-sale-to-secura-bio/
https://endpts.com/the-duvelisib-hot-potato-is-tossed-to-a-new-owner-as-verastem-looks-to-reorganize-around-the-pipeline/
https://www.businesswire.com/news/home/20200129005392/en/Verastem-Oncology-Announces-Dosing-Patient-CSPC%E2%80%99s-Chinese
https://www.businesswire.com/news/home/20191207005012/en/Verastem-Oncology-Presents-Phase-2-PRIMO-Study/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
https://www.businesswire.com/news/home/20191106005590/en/Verastem-Oncology-Present-Phase-2-PRIMO-Study/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://www.biospace.com/article/arcellx-rakes-in-85-million-series-b-round-for-improved-cell-therapies/
https://www.biospace.com/article/releases/verastem-oncology-receives-orphan-drug-designation-from-fda-for-copiktra-for-the-treatment-of-t-cell-lymphoma/
https://www.raps.org/news-and-articles/news-articles/2019/9/fda-issues-53-product-specific-guidances-to-help-w
https://www.thepharmaletter.com/article/verastem-oncology-out-licenses-copiktra
https://www.fiercepharma.com/pharma/drugmakers-brought-15-new-oncology-meds-to-market-last-year-as-spending-continued-to-climb
https://www.businesswire.com/news/home/20190515006006/en/Verastem-Oncology-Present-New-COPIKTRA%E2%84%A2-Duvelisib-Dose/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://endpts.com/the-2018-breakdown-on-fda-new-drug-approvals-with-the-top-4-trends-in-play/
https://markets.businessinsider.com/news/stocks/catalent-and-verastem-oncology-partner-on-newly-launched-fda-approved-copiktra-duvelisib-capsules-1027622441
https://www.biospace.com/article/releases/verastem-oncology-announces-pricing-of-registered-direct-offering-of-150-million-of-convertible-notes/
https://www.biospectrumasia.com/news/25/11799/cspc-pharma-verastem-sign-license-agreement-for-cancer-treatment.html
https://seekingalpha.com/article/4209615-verastem-now-major-freshly-derisked-small-cap-oncology-opportunity?ifp=0
https://endpts.com/fattaey-out-dentzer-up-at-curis-verastem-scores-china-deal-for-duvelisib/
http://www.pharmatimes.com/news/us_clears_verastems_copiktra_for_blood_cancers_1253402
https://www.fiercepharma.com/pharma/more-than-half-america-s-highest-salaries-are-paid-by-pharma-companies-report
https://endpts.com/novartis-punts-a-late-stage-pi3k-drug-with-a-worrying-safety-profile-to-one-of-chinas-upstart-biotechs/
https://www.fiercebiotech.com/biotech/asco18-roche-punts-taselisib-after-weak-data-severe-side-effects
https://endpts.com/roche-dumps-its-phiii-pi3k-effort-on-taselisib-after-researchers-track-poor-survival-edge-harsh-side-effects-for-breast-cancer/
https://endpts.com/verastem-takes-abbvies-blood-cancer-castoff-to-the-fda/
http://www.businesswire.com/news/home/20171031005343/en/Verastem-Announces-Regulatory-Strategy-Duvelisib-New-Drug
http://www.prnewswire.com/news-releases/infinity-regains-worldwide-rights-to-duvelisib-following-mutual-agreement-with-abbvie-to-end-collaboration-300291148.html
http://www.fiercebiotech.com/inifinity-pharma-back-under-a-cloud-after-duvelisib-disappoints-phii
Market Place
Share 
